News
ATNM
7.06
+1.44%
0.10
Weekly Report: what happened at ATNM last week (0415-0419)?
Weekly Report · 2d ago
Actinium Pharmaceuticals: A Strong Buy on Regulatory Advances and Strategic Positioning
TipRanks · 6d ago
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients with acute myeloid leukemia. Results from the Phase 3 SIERRA trial were presented at the 50th Annual European Bone Marrow Transplant Society Meeting in Glasgow, Scotland. Actinium Pharmaceuticals is a leader in the development of targeted radiotherapies.
PR Newswire · 6d ago
Weekly Report: what happened at ATNM last week (0408-0412)?
Weekly Report · 04/15 09:49
Weekly Report: what happened at ATNM last week (0401-0405)?
Weekly Report · 04/08 09:51
Actinium Pharmaceuticals: Strong Buy Rating on Financial Health and Promising Pipeline
TipRanks · 04/03 19:45
Actinium Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 04/01 14:27
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)
TipRanks · 04/01 14:20
HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
Benzinga · 04/01 14:16
Actinium Pharmaceuticals Price Target Maintained With a $21.00/Share by Cantor Fitzgerald
Dow Jones · 04/01 12:32
Cantor Fitzgerald Reiterates Overweight on Actinium Pharma, Maintains $21 Price Target
Benzinga · 04/01 12:24
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
Results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society in Glasgow, Scotland. The results demonstrate the potential of the treatment for patients with TP53 mutations. Actinium is a leader in the development of targeted radiotherapies. The Company's IomAB-B is a targeted radiotherapy conditioning agent.
PR Newswire · 04/01 12:00
Weekly Report: what happened at ATNM last week (0325-0329)?
Weekly Report · 04/01 09:50
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
TipRanks · 03/28 11:30
Actinium Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 03/26 16:24
HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
Benzinga · 03/26 16:14
Actinium Pharmaceuticals: A Strong Buy on Clinical Advancements and Strategic Positioning in the Radiopharmaceutical Sector
TipRanks · 03/26 14:55
Weekly Report: what happened at ATNM last week (0318-0322)?
Weekly Report · 03/25 09:52
Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more
Several key companies are set to release their earnings reports for the week of March 25 to 29. Walgreens Boots Alliance, Carnival, GameStop and more are among the companies scheduled to report next week. The week is shortened by a market holiday on Friday and will be shortened to one day.
Seeking Alpha · 03/24 12:01
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Actinium Pharmaceuticals (ATNM)
TipRanks · 03/20 16:50
More
Webull provides a variety of real-time ATNM stock news. You can receive the latest news about Actinium Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About ATNM
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.